Dillman R O
Hoag Cancer Center, Newport Beach, CA 92658.
Mol Biother. 1990 Dec;2(4):201-7.
Chemotherapy and biotherapy are the two systemic modalities available for cancer treatment. In vitro assays and animal studies suggest various rationales for combining these two modalities. The first approach is to take advantage of apparent additive or synergistic cytotoxic and/or cytostatic effects of both modalities. A second approach is the use of chemotherapy to maximally cytoreduce tumor, followed by biotherapy to restore the immune system and/or to enhance immunologic elimination of microscopic tumor. The third approach uses biotherapy to diminish chemotherapy toxicities so that higher and more intense doses of chemotherapy can be used. The fourth approach involves the use of biologics to modify the tumor environment in order to enhance the delivery of chemotherapy molecules. A fifth approach is the use of chemotherapy as a biologic response modifier to enhance antitumor effects of biotherapy. The sixth strategy is to use biologics to reduce or overcome cell resistance to chemotherapy. Clinical trials are in progress exploring these various strategies. The end point of all of these approaches must be an improved risk to benefit or toxicity to efficacy ratio in the context of cancer treatment.
化疗和生物疗法是可用于癌症治疗的两种全身治疗方式。体外试验和动物研究为联合使用这两种治疗方式提供了各种理论依据。第一种方法是利用两种治疗方式明显的相加或协同细胞毒性和/或细胞抑制作用。第二种方法是先用化疗最大限度地减少肿瘤细胞数量,然后用生物疗法恢复免疫系统和/或增强对微小肿瘤的免疫清除。第三种方法是使用生物疗法减轻化疗毒性,以便能够使用更高剂量和更强效的化疗。第四种方法是使用生物制剂改变肿瘤环境,以增强化疗分子的递送。第五种方法是将化疗用作生物反应调节剂,以增强生物疗法的抗肿瘤作用。第六种策略是使用生物制剂降低或克服细胞对化疗的耐药性。目前正在进行临床试验探索这些不同的策略。在癌症治疗中,所有这些方法的终点都必须是改善风险效益比或毒性疗效比。